Pulmatrix Historical Balance Sheet
PULM Stock | USD 6.29 0.25 4.14% |
Trend analysis of Pulmatrix balance sheet accounts such as Short and Long Term Debt Total of 7.8 M, Other Current Liab of 543.9 K, Total Current Liabilities of 5.3 M or Property Plant And Equipment Net of 12 M provides information on Pulmatrix's total assets, liabilities, and equity, which is the actual value of Pulmatrix to its prevalent stockholders. By breaking down trends over time using Pulmatrix balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Pulmatrix latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Pulmatrix is a good buy for the upcoming year.
Pulmatrix Inventory |
|
Pulmatrix |
About Pulmatrix Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Pulmatrix at a specified time, usually calculated after every quarter, six months, or one year. Pulmatrix Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Pulmatrix and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Pulmatrix currently owns. An asset can also be divided into two categories, current and non-current.
Pulmatrix Balance Sheet Chart
Add Fundamental
Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Total Assets
Total assets refers to the total amount of Pulmatrix assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Pulmatrix books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Pulmatrix balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Pulmatrix are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most accounts from Pulmatrix's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Pulmatrix current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.At this time, Pulmatrix's Accounts Payable is very stable compared to the past year. As of the 27th of November 2024, Cash is likely to grow to about 20.5 M, while Other Stockholder Equity is likely to drop about 175.4 M.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 2.3M | 857K | 8.8M | 7.8M | Total Assets | 58.8M | 41.0M | 34.0M | 30.4M |
Pulmatrix balance sheet Correlations
Click cells to compare fundamentals
Pulmatrix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pulmatrix balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Stockholder Equity | 11.0M | 23.1M | 47.4M | 31.1M | 18.0M | 18.9M | |
Retained Earnings | (215.2M) | (234.5M) | (254.6M) | (273.5M) | (287.6M) | (273.2M) | |
Common Stock Shares Outstanding | 836.7K | 1.4M | 2.7M | 3.4M | 3.7M | 3.8M | |
Other Stockholder Equity | 226.2M | 257.6M | 301.0M | 304.6M | 305.6M | 175.4M | |
Total Assets | 36.1M | 38.2M | 58.8M | 41.0M | 34.0M | 30.4M | |
Other Current Liab | 2.5M | 893K | (198K) | 781K | 518K | 543.9K | |
Total Current Liabilities | 17.2M | 8.3M | 4.4M | 5.0M | 3.9M | 5.3M | |
Property Plant And Equipment Net | 900K | 1.9M | 2.4M | 945K | 11.5M | 12.0M | |
Current Deferred Revenue | 13.4M | 4.2M | 939K | 1.3M | 618K | 648.9K | |
Net Debt | (22.8M) | (29.9M) | (51.6M) | (34.8M) | (10.4M) | (10.9M) | |
Accounts Payable | 600K | 851K | 839K | 1.2M | 1.9M | 2.0M | |
Cash | 23.4M | 31.7M | 53.8M | 35.6M | 19.2M | 20.5M | |
Non Current Assets Total | 4.7M | 5.6M | 4.0M | 2.8M | 13.1M | 8.2M | |
Cash And Short Term Investments | 23.4M | 31.7M | 53.8M | 35.6M | 19.2M | 20.5M | |
Net Receivables | 7.2M | 84K | 67K | 1.3M | 928K | 1.0M | |
Liabilities And Stockholders Equity | 36.1M | 38.2M | 58.8M | 41.0M | 34.0M | 30.4M | |
Non Current Liabilities Total | 7.9M | 6.8M | 6.9M | 4.8M | 12.1M | 12.7M | |
Other Current Assets | 221K | 723K | 871K | 1.1M | 1.1M | 566.2K | |
Total Liab | 25.1M | 15.0M | 11.4M | 9.8M | 16.0M | 9.9M | |
Property Plant And Equipment Gross | 900K | 361.0 | 2.4M | 945K | 13.2M | 13.9M | |
Total Current Assets | 31.4M | 32.5M | 54.8M | 38.1M | 20.8M | 22.2M | |
Short Term Debt | 675K | 2.3M | 2.9M | 1.7M | 858K | 815.1K | |
Net Tangible Assets | 7.4M | 19.6M | 46.4M | 31.1M | 35.8M | 37.6M | |
Retained Earnings Total Equity | (174.0M) | (194.6M) | (215.2M) | (234.5M) | (211.0M) | (221.6M) | |
Capital Surpluse | 184.1M | 206.4M | 226.2M | 257.6M | 296.2M | 191.7M | |
Property Plant Equipment | 270K | 1.9M | 2.4M | 945K | 1.1M | 991.8K | |
Net Invested Capital | 11.0M | 23.1M | 46.4M | 31.1M | 18.0M | 24.3M | |
Net Working Capital | 14.2M | 24.3M | 50.3M | 33.1M | 16.9M | 21.6M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Revenue Per Share 3.119 | Quarterly Revenue Growth (0.16) | Return On Assets (0.30) | Return On Equity (0.59) |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.